Find Patient Assistance
Case Managers (CMs) partner closely with Partnership and Access Liaisons (PALs) and you to help patients understand the health insurance process and identify potential financial support options for Evrysdi.
ACTEMRA® (tocilizumab)
ALECENSA® (alectinib)
Avastin® (bevacizumab)
COLUMVI® (glofitamab-gxbm)
COTELLIC® (cobimetinib)
ENSPRYNG™ (satralizumab-mwge)
Erivedge® (vismodegib)
Evrysdi® (risdiplam)
GAZYVA® (obinutuzumab)
HEMLIBRA® (emicizumab-kxwh)
Herceptin® (trastuzumab)
Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk)
Itovebi™ (inavolisib)
KADCYLA® (ado-trastuzumab emtansine)
LUCENTIS® (ranibizumab injection)
LUNSUMIO® (mosunetuzumab-axgb)
OCREVUS® (ocrelizumab) and OCREVUS ZUNOVO® (ocrelizumab & hyaluronidase-ocsq)
PERJETA® (pertuzumab)
PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
PiaSky™ (crovalimab-akkz)
POLIVY® (polatuzumab vedotin-piiq)
Pulmozyme® (dornase alfa) Inhalation Solution
Rituxan® (rituximab) for Rheumatoid Arthritis (RA)
RITUXAN® (rituximab) for Oncology
Rituxan® (rituximab) for Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV)
RITUXAN HYCELA® (rituximab/hyaluronidase human)
ROZLYTREK® (entrectinib)
SUSVIMO® (ranibizumab injection)
TECENTRIQ® (atezolizumab)
TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs)
VABYSMO® (faricimab-svoa)
VENCLEXTA® (venetoclax tablets)
XOLAIR® (omalizumab) for subcutaneous use
ZELBORAF® (vemurafenib)
Oncology
Ophthalmology
Rheumatology
The Evrysdi Co-pay Program
If you have commercial health insurance and meet other eligibility criteria, the Evrysdi Co-pay Program may be able to help you pay for your medicine.*
Referrals to Independent
Co-pay Assistance Foundations
If eligible publicly or commercially insured patients have difficulty paying for their co-pay, co-insurance or other out-of-pocket costs, a Case Manager can refer them to an independent co-pay assistance foundation supporting their disease state.†
The Genentech Patient Foundation
If patients don't have health insurance coverage or have financial concerns and meet eligibility criteria, they may be able to get free medicine from the Genentech Patient Foundation.‡
*Eligibility criteria and benefit limits apply. Not valid for patients whose prescriptions are reimbursed under any federal or state government programs to pay for their Genentech medicine. Patients must be taking the Genentech medicine for an FDA-approved indication. Please visit the Co-pay Program website for the full list of Terms and Conditions.
†Independent co-pay assistance foundations have their own rules for eligibility. Genentech has no involvement or influence in independent foundation decision-making or eligibility criteria and does not know if a foundation will be able to help your patient. We can only refer your patient to a foundation that supports their disease state. Genentech does not endorse or show preference for any particular foundation. The foundations to which we refer your patient may not be the only ones that might be able to help.
‡To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine should try to pursue other forms of financial assistance, if available, and meet certain income requirements. Uninsured patients and insured patients without coverage for their medicine must meet a different set of income requirements. Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.
For assistance, call (877) GENENTECH/(877) 436-3683
6 a.m.–5 p.m. PT, Monday through Friday
To enroll in MySMA Support, complete and submit the Evrysdi Start Form